Lexeo Therapeutics - LXEO Company Short-Term Debts

LXEO (lexeotx.com) - company brandmark

Lexeo Therapeutics (LXEO) specializes in developing innovative gene therapy drugs. The market price action reflects the current 0.00 metric. The business is protected by exclusive patents in the treatment of cardiomyopathies and Alzheimer's disease, creating barriers to entry for new players. The development model relies on high scalability: following the R&D phase, mass production of drugs guarantees colossal revenue with low costs.

Lexeo (LXEO) - Company Short-Term Indebtedness from 02/21/2024 to 10/30/2026

Analytical breakdowns and data insights for company Lexeo Therapeutics Inc. (LXEO)

- current quotes and average value forecast:
Price Chart Lexeo|LXEO - Price Target Chart
- issuer market value details:
Market Capitalization Lexeo Therapeutics, Inc.|LXEO - Total Enterprise Value
- business book valuation details:
Accounting Value per Share Lexeo Therapeutics|LXEO - Accounting Capitalization|Market Capitalization to Book Value Ratio lexeotx.com|LXEO - Company Assets
- debt and liquidity details:
Debt to Equity Lexeo Therapeutics|LXEO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Lexeo|LXEO - Aggregate Debt Obligations|Debt to Book Value Lexeo Therapeutics, Inc.|LXEO - Amount of Long-Term Liabilities|Company Short-Term Debts Lexeo Therapeutics|Quick Ratio lexeotx.com
- earnings and valuation multiples indicators:
LXEO - Company Net Income
General company analysis:lexeotx.com - LXEO
Mass-produced product of Lexeo Therapeutics

Lexeo Therapeutics (LXEO) focuses on capital-intensive clinical trials for gene therapy. The dynamics of short-term financial debt reflect the current volume of obligations maturing within one year. This metric measures the pressure on liquidity and the business's ability to service loans without external support. For a venture biotech, rising debt confirms creditor confidence in management's competencies, while a decrease in the indicator signals the strengthening of the company's financial autonomy.

Who Lexeo Therapeutics competes with

TEM - Company Short-Term Debt|QGEN: Company Short-Term Debt|IONS: Company Short-Term Debts|Short-Term Debt Repligen Inc. (RGEN)|Company Current Liabilities RNA|Company Short-Term Indebtedness CRSP (crisprtx.com)|Company Short-Term Debts WGS|RARE - Short-Term Debt|Company Short-Term Debt Beam Therapeutics Corp BEAM|Sarepta Corp (SRPT) - Short-Term Debt|TWST: Company Current Liabilities|Company Short-Term Loans and Borrowings TXG (10xgenomics.com)|NTLA (Intellia Therapeutics, Inc.) - Company Current Liabilities|STOK: Amount of Current Liabilities|BLFS (BioLife Corp) - Company Short-Term Debts|WVE: Company Short-Term Loans and Borrowings|Company Short-Term Debts MAZE|SION - Short-Term Debt|Company Short-Term Debt Prime Medicine PRME|Company Short-Term Loans and Borrowings TSHA|uniQure Corp - Company Short-Term Debts|MGTX - Company Short-Term Debts|REGENXBIO Inc. (RGNX) - Company Short-Term Debt|Current Liabilities SLDB (solidbio.com)|OCGN (Ocugen) - Company Short-Term Debts|Short-Term Debt Pacific Biosciences of California, Inc. PACB|Company Current Liabilities BNTC (Benitec)|Company Short-Term Debts Design Corp (DSGN)|Rocket Pharmaceuticals - Company Current Liabilities|Amount of Current Liabilities FDMT (4dmoleculartherapeutics.com)|Korro Bio, Inc - Company Short-Term Debts|Short-Term Debt Volume Editas Medicine Inc EDIT|SLN: Company Short-Term Debts|Company Current Liabilities ProQR Therapeutics|Company Short-Term Debt Codexis Inc|sangamo.com (SGMO) - Short-Term Debt Volume|Company Short-Term Debt Nautilus Biotechnology (NAUT)|Company Short-Term Debt MGX (Metagenomi Inc.)|Precision BioSciences - Company Current Liabilities|GBIO: Company Short-Term Indebtedness|Boundless Bio, Inc. - Company Short-Term Debts|Short-Term Debt Exicure, Inc.|imunon.com (IMNN) - Company Short-Term Debt|Short-Term Debt Phio Pharmaceuticals Corp. (PHIO)|MBIO (Mustang Bio Inc) - Company Short-Term Debts|Company Short-Term Indebtedness RNAZ (TransCode)|Company Short-Term Debt Bionano Genomics, Inc. (BNGO)|adnas.com - Company Short-Term Indebtedness|Company Short-Term Debts BLUE (bluebird bio)|Company Short-Term Debts ImmunoPrecise Antibodies Ltd IPA|OMGA - Company Short-Term Debt|OMIC: Company Short-Term Debt|RGLS: Company Short-Term Debts|Short-Term Debt syros.com (SYRS)|Company Current Liabilities TBIO|Company Short-Term Indebtedness TCON (TRACON Pharmaceuticals Inc.)|Company Short-Term Debts UBX